A $1 Billion Pennsylvania cell therapy site investment bolsters domestic manufacturing, creating 500 skilled biomanufacturing ...
Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly ...
In this episode of Ask the Expert, Susan J. Schniepp, Nelson Labs, and Siegfried Schmitt, Parexel, discuss the benefits of orphan drug development and how a mid-sized company can work with regulators ...
One challenge is limited commercial synergy. Rare disease markets are often fragmented, with small prescriber bases and ...
FDA has accepted the NDA for BMS's Iberdomide, an oral agent targetting relapsed/refractory multiple myeloma.
The European approval for GSK's depemokimab joins recently announced data on vaccine efficacy and progress on 4-month viral treatments.
Roche. Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease. 2026 Feb 16. Accessed 2026 Feb 16.
Kent Malmros is senior director of training at Veeva Systems. He has spent the majority of his career delivering technology-enabled training solutions to life-sciences companies and has held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results